Skip to main content
Premium Trial:

Request an Annual Quote

OliX Licenses AMD Drug to YuYu Pharma

Premium

NEW YORK (GenomeWeb) – Korean RNAi drug developer OliX Pharmaceuticals, formerly known as Biomolecular Therapeutics, announced today that it has licensed its siRNA-based age-related macular degeneration drug to YuYu Pharma.

The drug, called OLX301, comprises OliX's proprietary self-delivering siRNAs. Under the terms of the arrangement, YuYu will take over the drug's development, manufacturing, and commercialization. In exchange, OliX is eligible to receive milestone payments based on the drug's development and regulatory approval, as well as tiered royalties on product sales.

Additional terms of the deal were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more